Cardinal Health (CAH)
(Delayed Data from NYSE)
$100.66 USD
-0.01 (-0.01%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $100.64 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$100.66 USD
-0.01 (-0.01%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $100.64 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) strength in business raises optimism about the stock.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cardinal Health (CAH) Gets FDA Warning for Monoject Syringes
by Zacks Equity Research
The FDA is alerting healthcare providers and facilities against the use of Cardinal Health's (CAH) Monoject syringes with syringe pumps and PCS pumps.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
by Zacks Equity Research
Here is how Arch Therapeutics, Inc. (ARTH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.
Why You Should Add Integer Holdings (ITGR) to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Is Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OMFL
Zacks.com featured highlights Cboe Global, Parker-Hannifin, Microsoft, FedEx and Cardinal Health
by Zacks Equity Research
Cboe Global, Parker-Hannifin, Microsoft, FedEx and Cardinal Health have been highlighted in this Screen of The Week article.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
5 Top Dividend Growth Stocks for Your Portfolio
by Sweta Killa
Cboe Global Markets (CBOE), Parker-Hannifin (PH), Microsoft (MSFT), FedEx (FDX) and Cardinal Health (CAH) could be solid choices for your portfolio.
4 Growth Stocks to Take Advantage of the November Rally
by Tirthankar Chakraborty
With things looking up for the stock market this November, investing in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cardinal Health (CAH) and Runway Growth Finance (RWAY) seems prudent.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal Health (CAH) Launches Surgical Gown for Safe Surgery
by Zacks Equity Research
Cardinal Health's (CAH) SmartGown EDGE Breathable Surgical Gown will enable clinical teams to focus on delivering safe patient care by reducing instrument handoffs and contamination.
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.